Polivy 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0020 
C.I.13 - Other variations not specifically covered 
16/03/2023 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
N/0022 
Minor change in labelling or package leaflet not 
10/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
PSUSA/10817
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
polatuzumab vedotin 
II/0018 
Submission of the final report from study GO29365 
12/01/2023 
n/a 
listed as a category 3 study in the RMP in order to 
address MEA/002. This is a phase Ib/II, multicenter, 
open-label study evaluating the safety, tolerability, 
and anti-tumor activity of polatuzumab vedotin in 
combination with rituximab or obinutuzumab plus 
bendamustine in patients with R/R follicular 
lymphoma or R/R diffuse large B-cell lymphoma. The 
RMP version 3.0 has also been submitted. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0017/G 
This was an application for a group of variations. 
15/09/2022 
n/a 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10817
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
polatuzumab vedotin 
II/0012 
Please refer to the Recommendations section above. 
24/03/2022 
24/05/2022 
SmPC and PL 
Please refer to Scientific Discussion ‘Polivy-H-C-4870-II-
0012’ 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IG/1496 
A.7 - Administrative change - Deletion of 
18/03/2022 
n/a 
manufacturing sites 
II/0014/G 
This was an application for a group of variations. 
17/03/2022 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
II/0013/G 
This was an application for a group of variations. 
27/01/2022 
n/a 
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
PSUSA/10817
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
polatuzumab vedotin 
R/0008 
Renewal of the marketing authorisation. 
14/10/2021 
03/12/2021 
IA/0011 
B.I.d.1.b.1 - Stability of AS - Change in the storage 
22/09/2021 
n/a 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
conditions - Change to more restrictive storage 
conditions of the AS 
IA/0010 
B.I.b.2.a - Change in test procedure for AS or 
26/08/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/10817
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
/202012 
polatuzumab vedotin 
IB/0007 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
05/05/2021 
03/12/2021 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
PSUSA/10817
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
polatuzumab vedotin 
R/0003 
Renewal of the marketing authorisation. 
15/10/2020 
09/12/2020 
SmPC, Annex 
The CHMP, having reviewed the available information on 
IA/0005 
A.4 - Administrative change - Change in the name 
04/12/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
II, Labelling 
the status of the fulfilment of Specific Obligations and 
and PL 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Polivy, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
II/0002/G 
This was an application for a group of variations. 
15/10/2020 
09/12/2020 
SmPC, 
Labelling and 
PL 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
life of the finished product - After dilution or 
Page 6/7 
 
 
 
 
 
 
 
 
reconstitution (supported by real time data) 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
13/03/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
